{"entity":{"id":"seven-plus-three","kind":"term","name":"7+3 induction chemotherapy","aka":["7+3","7 + 3","cytarabine-anthracycline","cytarabine plus daunorubicin","intensive chemotherapy","intensive induction","non-intensive","non-intensive therapy","less intensive","CPX-351","Vyxeos","HiDAC","high-dose cytarabine","FLAG-IDA"],"tldr":"The classic first treatment for acute myeloid leukaemia, unchanged since 1973: seven days of continuous cytarabine plus three days of an anthracycline, given in hospital. Fit patients still get it, now with a targeted drug added according to their leukaemia's genetics.","summary":"7+3 achieves complete remission in 60-80% of younger adults and is followed by consolidation (high-dose cytarabine) or allogeneic transplant depending on ELN risk. Additions by genotype: midostaurin or quizartinib for FLT3 mutations, gemtuzumab ozogamicin for favourable-risk CD33-positive disease, CPX-351 (liposomal 7+3) for secondary AML. Patients unfit for intensive chemotherapy receive venetoclax plus azacitidine, which is eroding the boundary between 'intensive' and 'non-intensive' approaches. Induction mortality is 5-10% and the main risks are infection and bleeding during weeks of aplasia.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Acute_myeloid_leukemia#Treatment","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Acute_myeloid_leukemia#Treatment"}],"tags":[],"related":["induction-therapy","anthracycline","hma","allogeneic-transplant"],"cancers":["aml"],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":["venetoclax","azacitidine","midostaurin","gilteritinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Treatment jargon"},"route":"/terms/seven-plus-three/","neighbours":{"term":[{"id":"allogeneic-transplant","kind":"term","name":"Allogeneic stem cell transplant (allo-SCT)","route":"/terms/allogeneic-transplant/"},{"id":"anthracycline","kind":"term","name":"Anthracyclines (doxorubicin, epirubicin)","route":"/terms/anthracycline/"},{"id":"hma","kind":"term","name":"Hypomethylating agents (azacitidine, decitabine)","route":"/terms/hma/"},{"id":"induction-therapy","kind":"term","name":"Induction therapy","route":"/terms/induction-therapy/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/"}],"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/"},{"id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}]}}